This announcement comes after Pfizer mentioned its vaccine must be saved at -70 levels Celsius or else it falls aside.
The coronavirus vaccine being developed by Sanofi will not must be super-cooled and a traditional fridge will suffice, the Paris-based drugmaker’s France chief Olivier Bogillot mentioned Sunday.
His feedback got here days after American pharmaceutical big Pfizer and its German accomplice BioNTech introduced that their vaccine had confirmed 90 % efficient in stopping COVID-19 infections in ongoing Section 3 trials involving greater than 40,000 folks.
The businesses mentioned they anticipate to provide as much as 50 million vaccine doses globally in 2020, and as much as 1.3 billion doses in 2021.
Nevertheless, Pfizer’s vaccine have to be saved at -70 levels Celsius (-94 levels Fahrenheit) or else it falls aside, effectively past the potential of most hospital freezers not to mention home home equipment.
Rachel Silverman, a coverage fellow on the Heart for International Growth, has already warned that sustaining the Pfizer vaccine’s “ultra-cold chain” from manufacturing unit to sufferers’ arms constitutes “an unlimited logistical problem even within the West”.
“Our vaccine will likely be just like the ‘flu vaccine, you may hold it in your fridge,” thus avoiding the issue, Bogillot informed the CNews channel.
“This will likely be a bonus for some nations,” he added.
The Sanofi vaccine, one in all many in improvement, will likely be out there for distribution subsequent June, Bogillot added.
The outcomes of the Section 2 checks, involving lots of of individuals, will likely be made public in early December, he added. If these outcomes are optimistic then Section 3 trials involving 1000’s of individuals will start, alongside mass manufacturing.
Eleven of the vaccines underneath improvement have already begun Section 3 trials.
The Pfizer vaccine is “a bit of extra superior” within the improvement course of, mentioned Bogillot, however “one laboratory shouldn’t be going to have the ability to provide the doses for the entire planet.
“We might want to have a number of winners on the finish of this race.”
The Sanofi product will even be made avaiable at an “inexpensive” value he mentioned, with out giving particulars.